Cancer clinical trials in the region Grand Est
288 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 1 / Phase 2
Endometrial cancer
#NCT04104776
#2023-508002-20-00
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
ARID1A
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Novartis Pharmaceuticals
Phase 1 / Phase 2
Lung cancer
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT04104776
#2023-508002-20-00
Required histologic types
Mesothelium
Primary peritoneal cancer (PPC)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Novartis Pharmaceuticals
Phase 1 / Phase 2
Lymphoma
#NCT04104776
#2023-508002-20-00
Required histologic types
B cell lymphoma
T cell lymphoma
Required histologic sub types
Large B cell lymphoma
Peripheral T cell lymphoma
Required central nervous system lesions
None
Treated / Controled
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
Allogeneic stem cell transplant
5 recruiting sites
Novartis Pharmaceuticals
Phase 1 / Phase 2
Endometrial cancer
#NCT04104776
#2023-508002-20-00
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded genetic anomalies
ARID1A
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Novartis Pharmaceuticals
Phase 1 / Phase 2
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT04104776
#2023-508002-20-00
Required histologic types
Epithelial ovarian cancer
Required histologic sub types
Clear cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
ARID1A
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Novartis Pharmaceuticals
Phase 1 / Phase 2
Prostate cancer
#NCT04104776
#2023-508002-20-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Novartis Pharmaceuticals
Phase 1 / Phase 2
Breast cancer
Stomach and esophageal cancer
#NCT06324357
#2023-509566-38-00
Required histologic types
Stomach
Oesogastric junction
Esophagus
Required histologic sub types
Adenocarcinoma
Required HER2 statuses
HER2 Positive
Required disease stage
Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Boehringer Ingelheim
Phase 1 / Phase 2
Breast cancer
Stomach and esophageal cancer
#NCT06324357
#2023-509566-38-00
Required histologic types
Stomach
Oesogastric junction
Esophagus
Required histologic sub types
Adenocarcinoma
Required HER2 statuses
HER2 Positive
Required disease stage
Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Boehringer Ingelheim
Phase 1 / Phase 2
Breast cancer
Stomach and esophageal cancer
#NCT06324357
#2023-509566-38-00
Cohortes I, I-Ext, J et J-Ext
Required histologic types
Stomach
Oesogastric junction
Esophagus
Required histologic sub types
Adenocarcinoma
Required HER2 statuses
HER2 Positive
Required disease stage
Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Boehringer Ingelheim
Phase 1 / Phase 2
Breast cancer
Stomach and esophageal cancer
#NCT06324357
#2023-509566-38-00
Required histologic types
Stomach
Oesogastric junction
Esophagus
Required histologic sub types
Adenocarcinoma
Other
Required HER2 statuses
HER2 Positive
Required disease stage
Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Boehringer Ingelheim